BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Dull, R. O., & Hahn, R. G. (2022). The glycocalyx as a permeability barrier: Basic science and clinical evidence. Critical Care, 26(1), 273. Added by: Dr. Enrique Feoli (02/07/2025, 00:22) Last edited by: Dr. Enrique Feoli (02/07/2025, 00:23) |
 |
| Resource type: Journal Article DOI: 10.1186/s13054-022-04154-2 ID no. (ISBN etc.): 1364-8535 BibTeX citation key: Dull2022 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Glycobiology Keywords: Anesthesia, Capillaries, Fluid kinetics, Glycocalyx, Human studies, Permeability, Translational research Creators: Dull, Hahn Collection: Critical Care |
Views: 5/20
|
| Abstract |
|
Preclinical studies in animals and human clinical trials question whether the endothelial glycocalyx layer is a clinically important permeability barrier. Glycocalyx breakdown products in plasma mostly originate from 99.6–99.8\% of the endothelial surface not involved in transendothelial passage of water and proteins. Fragment concentrations correlate poorly with in vivo imaging of glycocalyx thickness, and calculations of expected glycocalyx resistance are incompatible with measured hydraulic conductivity values. Increases in plasma breakdown products in rats did not correlate with vascular permeability. Clinically, three studies in humans show inverse correlations between glycocalyx degradation products and the capillary leakage of albumin and fluid.
|